Comunicati.net - Comunicati pubblicati - precision business insights Comunicati.net - Comunicati pubblicati - precision business insights Mon, 19 Apr 2021 10:16:21 +0200 Zend_Feed_Writer 1.12.20 (http://framework.zend.com) http://comunicati.net/utenti/24029/1 Global Spinal Implants Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023 Thu, 08 Feb 2018 11:03:35 +0100 http://comunicati.net/comunicati/societa_civile/partiti/forza_italia/469032.html http://comunicati.net/comunicati/societa_civile/partiti/forza_italia/469032.html precision business insights precision business insights

Spine implants are used to treat deformities and disorders related to the spine. Spine disorders are primarily caused by degenerative conditions in spine, deformity, tumors, and trauma. In Spinal implants market, artificial disc replacement is seen as the relatively new approach to relieve the back pain. Artificial discs are designed with the goal of mimicking the form and function of the spines natural disc. Artificial disc replacement is generally seen as an alternative to the more common spinal fusion surgery that joints two vertebrae together.

 Global Market Outline: Spinal Implants Market

 With rising adoption of minimal risk spine surgeries, spinal implants market anticipated to grow at significant rate over the forecast period. Spinal implants have an advantage over the open spine surgeries like low risk of infection, pain, muscle damage, minimal blood loss and faster recovery time, all these factors are leading to increasing number of patients adopting spinal implants and driving market growth for spinal implant. In addition, rise in geriatric population and technological developments in bone grafting products are projected to drive the growth of spinal implant market over forecast period. However, stringent regulations, lack of adequate awareness about the new procedures among healthcare professional and patients, and the high cost of procedures are hindering the spinal implants market growth.

 

A sample of this report is available upon request @

https://www.precisionbusinessinsights.com/market-reports/global-spinal-implants-market/#ulp-4H8Z4LpNMLEuOnnx 

 

 

Spinal implants market has been segmented based on product type, surgery type, procedure type, and end-user

 

By product type, spinal implants market is segmented into

·         Spinal Fusion

·         Cervical Fusion

·         Thoraco–Lumbar Fusion

·         Vertebral Compression Fracture Treatment Devices

·         Balloon Kyphoplasty Devices

·         Vertebroplasty Devices

·         Non-Fusion Implants

·         Dynamic Stabilization devices

·         Artificial Discs

·         Annulus Repair Devices

·         Nuclear Disc Prosthesis

 

By surgery, spinal implants market is segmented into

·         Open Surgery

·         Minimally Invasive Surgery

 

Based on end-user, spinal implants market is segmented into

·         Hospitals

·         Orthopedic Clinics

·         Spine Centers

 

To view TOC of this report is available upon request @

https://www.precisionbusinessinsights.com/market-reports/global-spinal-implants-market/#ulp-c654SbFYO64MsOhu

 

 

Global spinal implants market is exhibiting steady growth with significant CAGR over the forecast period. Traditional spine surgery segment is dominated and accounted for the more share in spinal implants market. Rise in the preference for non-fusion procedures over the fusion procedures is one of the trends in spinal implants market. Government initiatives and technological developments in treatment and development of advanced spinal implants driving the spinal implants market revenue growth. For instance, the American Academy of Orthopedic Surgeons and North American Spine Foundation, both contribute towards the growth of spinal implants devices market through R&D funding and training programs for healthcare professionals globally.

 

Need more information about this report @

https://www.precisionbusinessinsights.com/market-reports/global-spinal-implants-market/#ulp-14mlyhjMGhVjZqa3

 

 

 

Geographically spinal implants market has been segmented into following regions viz. North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. North America is dominating the spinal implants market followed by Europe. Europe spine implants market is estimated to be dominated by new product launches and mergers & acquisitions. In 2014, Zimmer Hold Inc. launched virage OCT spinal fixation system. Moreover, increase in geriatric population and number of accidents boosting market revenue growth of spinal impants market in Europe region. According to census statistics number of people having age above 65 in Germany, Italy, UK, France and Spain together were 61, 806, 92. Asia Pacific is expected to be fastest growing market due to expansion row in health coverage, the rapid increase in healthcare infrastructure and increased funding of government on health care.

 

 

Some of the players in spinal implants market are Zimmer Biomet (U.S.), Johnson & Johnson Services Inc (U.S.), Stryker Corporation (U.S.), Benvenue Medical, Inc. (U.S.), Becton, Dickinson and Company (CareFusion Corporation) (U.S.), Alphatec Holdings, Inc. (Alohatec Spine, Inc.) (U.S.), Medtronic Plc (U.S.), Orthofix Holdings, Inc. (U.S.), and Globus Medical Inc. (U.S.) to name some few.

 

Get access to full summary @

https://www.precisionbusinessinsights.com/market-reports/global-spinal-implants-market/

 

]]>
Global Soft Tissue Sarcoma Treatment Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023 Thu, 08 Feb 2018 10:59:38 +0100 http://comunicati.net/comunicati/istituzioni/regioni/campania/469031.html http://comunicati.net/comunicati/istituzioni/regioni/campania/469031.html precision business insights precision business insights

Soft tissue sarcoma treatment market: Soft tissue sarcoma is the rare and diverse group of cancers that develop from soft tissues such as blood vessels, muscles, fats, nerves, and deep skin tissues etc. There are around 50 different types of soft tissue sarcoma have been identified, the common types of soft tissue sarcoma are liposarcomas which develop from fat cells, and leiomyosarcomas, which arise from smooth muscle tissue. The soft tissue sarcoma can be treated by the combined chemotherapy, radiotherapy, and surgery to remove the tumour. If surgical procedure is not required, chemotherapy alone can be used.

 Global Market Outline: Soft Tissue Sarcoma Treatment Market 

 Increase in the prevalence and incidence of different types of cancers, rise in the number of soft tissue sarcoma cases, increase in the R&D activities on drugs and other biological therapies, patent expiry of branded drugs, increase in the healthcare expenditure and rise in quality patient care are expected to fuel the soft tissue sarcoma treatment market over the forecast period. However, high cost for the radiotherapy and chemotherapy, stringent regulatory guidelines, and adverse effects associated with the treatment might hinder the growth of soft tissue sarcoma treatment market over the forecast timeframe.

 

A sample of this report is available upon request @

https://www.precisionbusinessinsights.com/market-reports/global-soft-tissue-sarcoma-treatment-market/#ulp-4H8Z4LpNMLEuOnnx

 

 

The soft tissue sarcoma treatment market has been segmented on basis of disease type, treatment type, and end user

 

Based on the treatment type, soft tissue sarcoma treatment market is segmented into following:

·         Targeted Therapy

·         Chemotherapy

·         Anti-angiogenesis drugs

·         Radiation Therapy

o    Internal Radiation Therapy

o    External Radiation Therapy

 

Based on the disease type, soft tissue sarcoma treatment market is segmented into following:

·         Local Sarcoma

·         Regional Sarcoma

·         Metastatic Sarcoma

 

Based on the distribution channel, soft tissue sarcoma treatment market is segmented into following:

·         Hospitals

·         Oncology Clinics

·         Long Term Care Centres

 

To view TOC of this report is available upon request @

https://www.precisionbusinessinsights.com/market-reports/global-soft-tissue-sarcoma-treatment-market/#ulp-c654SbFYO64MsOhu

 

 

Soft tissue sarcoma treatment market is in growing stage as very fewer products in the market are currently approved to treat various types of soft tissue sarcoma. Various international companies are very active in the soft tissue sarcoma treatment market in terms of product launches, research, and development activities. For instance, in 2012, Threshold Pharmaceuticals Inc. signed a global license and co-development agreement for Evofosfamide, which is the most advanced first-line drug for soft tissue sarcoma with Merck KGaA. Merck KGaA paid US$ 110 Mn as upfront payment and milestone payments to Threshold, and additionally, Merck KGaA covers 70% of all evofosfamide development expenses. GSK’s Votrient (pazopanib) is approved for second-line treatment, and another drug Aldoxorubicin is approved as first-line drug for the treatment of soft tissue sarcoma. Currently, doxorubicin is commonly used for the treatment of soft tissue sarcoma.

 

Need more information about this report @

https://www.precisionbusinessinsights.com/market-reports/global-soft-tissue-sarcoma-treatment-market/#ulp-14mlyhjMGhVjZqa3

 

 

Geographically, soft tissue sarcoma treatment market segmented into following regions Viz. North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. North America may lead the soft tissue sarcoma treatment market owing to increase in the prevalence of the disease. According to American Cancer Society, approximately 12,390 people in 2016 are suffering soft tissue sarcoma and cancer. Europe holds a key share in soft tissue sarcoma treatment market attributed to change in lifestyle, increase in R&D activities for the development of new drugs. Asia-Pacific region accounts for a significant growth due to increase in cancer cases, and rise in awareness about advanced soft tissue sarcoma treatment.

 

Some of the players in the soft tissue sarcoma treatment market are GlaxoSmithKline plc (U.K.), Eli Lilly and Company (U.S.), Pfizer, Inc. (U.S.), Bristol-Myers Squibb (U.S.), F. Hoffmann-La Roche AG (Genentech) (Switzerland), Johnson & Johnson Services, Inc. (U.S.), Teva Pharmaceutical Industries Ltd (Israel), and Celgene Corporation (U.S.) to name a few.

 

Get access to full summary @

https://www.precisionbusinessinsights.com/market-reports/global-soft-tissue-sarcoma-treatment-market/

]]>
Global Soft Tissue Sarcoma Treatment Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023 Thu, 08 Feb 2018 10:18:52 +0100 http://comunicati.net/comunicati/istituzioni/regioni/toscana/469024.html http://comunicati.net/comunicati/istituzioni/regioni/toscana/469024.html precision business insights precision business insights

Soft tissue sarcoma treatment market: Soft tissue sarcoma is the rare and diverse group of cancers that develop from soft tissues such as blood vessels, muscles, fats, nerves, and deep skin tissues etc. There are around 50 different types of soft tissue sarcoma have been identified, the common types of soft tissue sarcoma are liposarcomas which develop from fat cells, and leiomyosarcomas, which arise from smooth muscle tissue. The soft tissue sarcoma can be treated by the combined chemotherapy, radiotherapy, and surgery to remove the tumour. If surgical procedure is not required, chemotherapy alone can be used.

 Global Market Outline: Soft Tissue Sarcoma Treatment Market 

 Increase in the prevalence and incidence of different types of cancers, rise in the number of soft tissue sarcoma cases, increase in the R&D activities on drugs and other biological therapies, patent expiry of branded drugs, increase in the healthcare expenditure and rise in quality patient care are expected to fuel the soft tissue sarcoma treatment market over the forecast period. However, high cost for the radiotherapy and chemotherapy, stringent regulatory guidelines, and adverse effects associated with the treatment might hinder the growth of soft tissue sarcoma treatment market over the forecast timeframe.

 

A sample of this report is available upon request @

https://www.precisionbusinessinsights.com/market-reports/global-soft-tissue-sarcoma-treatment-market/#ulp-4H8Z4LpNMLEuOnnx

 

 

The soft tissue sarcoma treatment market has been segmented on basis of disease type, treatment type, and end user

 

Based on the treatment type, soft tissue sarcoma treatment market is segmented into following:

·         Targeted Therapy

·         Chemotherapy

·         Anti-angiogenesis drugs

·         Radiation Therapy

o    Internal Radiation Therapy

o    External Radiation Therapy

 

Based on the disease type, soft tissue sarcoma treatment market is segmented into following:

·         Local Sarcoma

·         Regional Sarcoma

·         Metastatic Sarcoma

 

Based on the distribution channel, soft tissue sarcoma treatment market is segmented into following:

·         Hospitals

·         Oncology Clinics

·         Long Term Care Centres

 

To view TOC of this report is available upon request @

https://www.precisionbusinessinsights.com/market-reports/global-soft-tissue-sarcoma-treatment-market/#ulp-c654SbFYO64MsOhu

 

 

Soft tissue sarcoma treatment market is in growing stage as very fewer products in the market are currently approved to treat various types of soft tissue sarcoma. Various international companies are very active in the soft tissue sarcoma treatment market in terms of product launches, research, and development activities. For instance, in 2012, Threshold Pharmaceuticals Inc. signed a global license and co-development agreement for Evofosfamide, which is the most advanced first-line drug for soft tissue sarcoma with Merck KGaA. Merck KGaA paid US$ 110 Mn as upfront payment and milestone payments to Threshold, and additionally, Merck KGaA covers 70% of all evofosfamide development expenses. GSK’s Votrient (pazopanib) is approved for second-line treatment, and another drug Aldoxorubicin is approved as first-line drug for the treatment of soft tissue sarcoma. Currently, doxorubicin is commonly used for the treatment of soft tissue sarcoma.

 

Need more information about this report @

https://www.precisionbusinessinsights.com/market-reports/global-soft-tissue-sarcoma-treatment-market/#ulp-14mlyhjMGhVjZqa3

 

 

Geographically, soft tissue sarcoma treatment market segmented into following regions Viz. North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. North America may lead the soft tissue sarcoma treatment market owing to increase in the prevalence of the disease. According to American Cancer Society, approximately 12,390 people in 2016 are suffering soft tissue sarcoma and cancer. Europe holds a key share in soft tissue sarcoma treatment market attributed to change in lifestyle, increase in R&D activities for the development of new drugs. Asia-Pacific region accounts for a significant growth due to increase in cancer cases, and rise in awareness about advanced soft tissue sarcoma treatment.

 

Some of the players in the soft tissue sarcoma treatment market are GlaxoSmithKline plc (U.K.), Eli Lilly and Company (U.S.), Pfizer, Inc. (U.S.), Bristol-Myers Squibb (U.S.), F. Hoffmann-La Roche AG (Genentech) (Switzerland), Johnson & Johnson Services, Inc. (U.S.), Teva Pharmaceutical Industries Ltd (Israel), and Celgene Corporation (U.S.) to name a few.

 

Get access to full summary @

https://www.precisionbusinessinsights.com/market-reports/global-soft-tissue-sarcoma-treatment-market/]]>
Global Graves Orbitopathy Market : Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023 Wed, 07 Feb 2018 12:14:52 +0100 http://comunicati.net/comunicati/societa_civile/ecologia_e_ambiente/468906.html http://comunicati.net/comunicati/societa_civile/ecologia_e_ambiente/468906.html precision business insights precision business insights

Graves’ ophthalmopathy is also called as thyroid-associated orbitopathy (TAO) and thyroid eye disease (TED), Graves’ orbitopathy (GO) is autoimmune inflammatory disorder of the tissues of periorbit and orbit that is characterized by the retraction of upper eyelid, lagging, swelling and redness of lid, bulging of eyes and conjunctivitis. Most commonly occurs in the individuals having Graves’ disease, and less commonly in the individuals having Hashimoto’s thyroiditis, or in the people with euthyroid. It is a part of systemic process of variable expression in skin, thyroid and eyes that is caused by the autoantibodies which binds to the tissues of these organs. Autoantibodies targets the fibroblasts in the eye muscles and fibroblasts can be differentiated into the fat cells (adipocytes). Muscles and fat cells expands and get inflammation.

 Increase in incidence and prevalence of thyroid disorders, availability of appreciative reimbursement policies for the treatment, and growing awareness regarding the complications related to thyroid disorders are some of the factors driving Graves’ disease market. Side effects associated with drugs are one of the restraints for the graves orbitopathy market.

 

A sample of this report is available upon request @

https://www.precisionbusinessinsights.com/market-reports/global-graves-orbitopathy-market/#ulp-4H8Z4LpNMLEuOnnx 

 

 

The global graves orbitopathy market is segmented on the basis of drug class, distribution channel and geographical regions.

 

Based on the drug class, the graves orbitopathy market is segmented as:

·         Iodine and Iodides

·         Ionic Inhibitors

·         Radioactive Iodine

·         Beta Blockers

·         Thioamides

·         Corticosteroids

 

Based on the distribution channel, the graves orbitopathy market is segmented as:

·         Hospital Pharmacies

·         Retail Pharmacies

·         Others

 

To view TOC of this report is available upon request @

https://www.precisionbusinessinsights.com/market-reports/global-graves-orbitopathy-market/#ulp-c654SbFYO64MsOhu

 

 

As per Wickham study in England, in 2016, Graves’ disease is accounted for 0.5 cases per 1000 persons, with high incidence rate in people with age of 40 to 60. Graves’ disease is the high prevalent autoimmune disorder in U.S After Hashimoto thyroiditis. In 2016, as per research study of PREGO (presentation of Graves orbitopathy), incidence of Graves’ orbitopathy in Europe was 10-30/10,000 human annually. However, severity and the incidence of the Graves’ disease in Europe was observed to decline to 2.10/10,000/year. Iodine-131 is used in radioactive iodine ablation (RIA) used to remove whole or a part of thyroid gland, which results in preventing the excessive production of thyroid hormone. Subtotal thyroidectomy used for the removal of thyroid gland is the most invasive treatment option.

 

Need more information about this report @

https://www.precisionbusinessinsights.com/market-reports/global-graves-orbitopathy-market/#ulp-14mlyhjMGhVjZqa3

 

 

 

On the basis of geographical regions, the graves’ orbitopathy market is segmented as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is expected as major market for the disorders related to thyroid gland followed by Europe. Asia-Pacific is expected to be as a rapidly growing market due to rise in thyroid gland disorders, rise in health care investments, growing awareness regarding hyperthyroidism, and different alternative treatments availability.

 

Some of the players in the graves orbitopathy disease market are GlaxoSmithKline plc (U.K.), Allergan, plc.(Ireland) Abbott Laboratories (U.S.) RLC LABS (U.S.), AbbVie, Inc.( U.S.), Mylan N.V.( U.S.), Pfizer, Inc. (U.S.), and Merck & Co.,Inc. (U.S.).

 

Get access to full summary @

https://www.precisionbusinessinsights.com/market-reports/global-graves-orbitopathy-market/

 

]]>
Global Glaucoma Surgery Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023 Wed, 07 Feb 2018 12:06:09 +0100 http://comunicati.net/comunicati/istituzioni/regioni/friuli_venezia_giulia/468897.html http://comunicati.net/comunicati/istituzioni/regioni/friuli_venezia_giulia/468897.html precision business insights precision business insights

Glaucoma Surgery Market: Glaucoma disease causes due to increase in intraocular pressure within the eye that damages the optic nerve and leads to loss of vision and even blindness. Glaucoma is second leading cause of irreversible blindness in the world. The most common types of glaucoma are open angle glaucoma and closed angle glaucoma. The common symptoms associated with glaucoma include eye pain, blurred vision, red eyes, light appears to extra halo-like glow around it, and vision problems with poor lighting. Glaucoma can be diagnosed by determining the intraocular pressure, the status of optic nerve and drainage angle, and visual fields. Glaucoma can be treated by using eye drops, laser treatments, and surgery.The global glaucoma surgery market is expected to grow at a significant CAGR due to increase in the geriatric population as they are more prone to eye diseases.

 Glaucoma Surgery Market Outline

 Rise in prevalence of glaucoma, new developments in minimally invasive glaucoma surgical devices, and increase in prevalence of diabetes and diabetic retinopathy expected to fuel the  glaucoma surgery market over the forecast period. Furthermore, changing lifestyle, unhealthy food, increase in incidence of ocular disorders, improved medical coverage, and increase in healthcare expenditure expected to bolster the global glaucoma surgery market. However, lack of awareness among key stakeholders about eye disorders, dearth of skilled professionals for glaucoma surgeries, stringent regulatory policies, and high cost of glaucoma surgery might hamper the growth of global glaucoma surgery market over the forecast period.

 

A sample of this report is available upon request @

https://www.precisionbusinessinsights.com/market-reports/global-glaucoma-surgery-market/#ulp-4H8Z4LpNMLEuOnnx 

 

 The glaucoma surgery market is segmented on the basis of disease type, surgery type, and end user

 

Based on surgery type, glaucoma surgery market has been segmented into the following:

·         Trabeculoplasty

·         Filtering surgery (viscocanalostomy)

·         Drainage implant (aqueous shunt implant)

·         Iridotomy

·         Others

 

Based on disease type, glaucoma surgery market has been segmented into the following:

·         Open-angle glaucoma

·         Closed-angle glaucoma

·         Low-tension glaucoma

·         Pigmentary glaucoma

·         Others

 

Based on end-user, glaucoma surgery market has been segmented into the following:

·         Hospitals

·         Ophthalmology Clinics

·         Ambulatory surgical centers

 

To view TOC of this report is available upon request @

https://www.precisionbusinessinsights.com/market-reports/global-glaucoma-surgery-market/#ulp-c654SbFYO64MsOhu

 

 

Market players are adopting different strategies to increase their market share in the glaucoma surgery market. Acquisitions & mergers, collaborations, technological developments such as inserting implants by minimally invasive surgical procedures, and organizing training programs for physicians regarding glaucoma surgeries expected to bolster the global glaucoma surgery market. For instance, in September 2016, Johnson & Johnson acquired Abbott Medical Optics business segments that include laser refractive surgery, cataract surgery, and consumer eye health. In December 2016, Ellex Medical Lasers conducted clinical training for physicians about operation of Ellex iTrack minimally invasive glaucoma surgery device in China. Moreover, approval of new products from various administrative bodies also propel the glaucoma surgery market growth. For instance, in March 2016, Glaukos Corporation announced that the company’s trabecular micro-bypass stent named iStent was approved in Japan by Japanese Ministry of Health, Labor and Welfare (MHLW). In August 2016, Alcon received FDA approval for the CyPass a micro-invasive surgical device to treat open-angle glaucoma. In the near future, pipeline products that can treat glaucoma are expected to create significant opportunities for the device manufacturers.

 

Need more information about this report @

https://www.precisionbusinessinsights.com/market-reports/global-glaucoma-surgery-market/#ulp-14mlyhjMGhVjZqa3

 

 

Geographically, the global glaucoma surgery market segmented into the following regions Viz. North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. North America accounts for the largest share followed by Europe and Asia-Pacific. North America holds dominant share in glaucoma surgery market which is mainly attributed to the availability of skilled professionals, increase in the incidence of glaucoma patients (according to Glaucoma Research Foundation survey, approximately one out of 10,000 babies born with glaucoma in United States), and increase in healthcare expenditure. Europe market is growing at significant CAGR owing to increase in the prevalence of glaucoma disease. In Europe, Italy has the highest prevalence for glaucoma disease that is approximately 182 prevalent cases per 100,000 population. Austria, Spain, and Germany also play a key role in Europe glaucoma surgery market due to the increase in prevalence cases. Asia-Pacific holds a key share due to increase in the geriatric population, rise in the prevalence of glaucoma disease patients majorly in India, China, and Japan.

 

Some of the players in glaucoma surgery market are Glaukos Corporation (U.S.), Ellex Medical Lasers (Australia), DOSE Medical Corporation (U.S.), Johnson & Johnson Services Inc., (U.S.), Abbott Laboratories (U.S.), and Alcon (Novartis) (U.S.) to name a few.

 

Get access to full summary @

https://www.precisionbusinessinsights.com/market-reports/global-glaucoma-surgery-market/

]]>
Global Genetic Analyzer Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023 Wed, 07 Feb 2018 10:54:22 +0100 http://comunicati.net/comunicati/societa_civile/partiti/alleanza_nazionale/468884.html http://comunicati.net/comunicati/societa_civile/partiti/alleanza_nazionale/468884.html precision business insights precision business insights

Genetic analysis is a method of learning and research in genetics and molecular biology fields that involves use of wide group of applications while basic system of the analysis is usually pertained to the orthodox genetics. Customary forms of analysis of genetic includes the gene identification and inherited diseases analysis. Genetic analysis also implicit the patients physical observation and the microscopic evaluation of genetics as it is conducted for the long time. Genetic analysis is also applied in differential diagnosis during the analysis of specific diseases, in mutation detection, copy number changes in DNA.

 Factors like advancements in the technologies of genetic testing, rise in prevalence of the genetic diseases, growing in the awareness are boosting the genetic analyser market globally. Furthermore, initiatives taken by the governments and increase in R&D investment and activities in the genetic field are also driving the genetic analyzer market. However, due to certain factors genetic analyzers use is restricted. The operability of such kind of automated advanced machines requires technical expertise leaving little room for human error. Calibration is essentially needed for genetic analyzers. High cost of genetic analyzers resulting in their availability in a limited number of research organizations is also hampering the growth of the genetic analyzers market globally.

 

 A sample of this report is available upon request @

https://www.precisionbusinessinsights.com/market-reports/global-genetic-analyzer-market/#ulp-4H8Z4LpNMLEuOnnx 

 

 

Global genetic analyzer market is segmented on the basis of instruments, consumables, application, end-user and geographical regions.

 

Based on product type, global genetic analyzer market is segmented as:

·         Instruments

o    DNA Microarrays

o    PCR

o    Next Generation Sequencing

o    Serial Analysis of Gene Expression

o    Northern Blotting

·         Consumables

o    DNA Chips

o    Reagents

 

Based on the end-user, global genetic analyzer market is segmented as:

·         Diagnostics Centres

·         Drug Discovery

·         Research and Development

·         Others

 

 

To view TOC of this report is available upon request @

https://www.precisionbusinessinsights.com/market-reports/global-genetic-analyzer-market/#ulp-c654SbFYO64MsOhu

 

 

Increase in the clinical genome sequencing, increase in incidence of neurodegeneration diseases such as Alzheimer’s, Huntington’s and Parkinson’s disease and also cases of cancers prompts the interest in genetic analysis. High swift in the acceptance of pediatric genetic testing used for of screening adult onset disorders are the factors contributing to the genetic analyzer market growth. Some of the government initiatives are improving the healthcare delivery to different sections of population, mergers, acquisitions and product launches of the companies are the factors driving the growth of the genetic analyzer market.

 

Need more information about this report @

https://www.precisionbusinessinsights.com/market-reports/global-genetic-analyzer-market/#ulp-14mlyhjMGhVjZqa3

 

 

Geographically, genetic analyzer market is divided into Europe, Asia-Pacific North America, Latin America, and Middle East and Africa. Global genetic analyser market is dominated by North America due to the rise in diseases prevalence by genetic disorders and rise in advancements technologically in the region. Asia-Pacific, is expected to show significant growth during the forecast period in the genetic testing market. India, China and Japan are expected as the fastest growing genetic testing markets in the Asia-Pacific region due to increase in R&D investment, a large pool of patients and rising government funding.

 

Some of the major companies dealing in genetic testing market are Thermo Fisher Scientific Inc. (U.S.), BioRad Laboratories (U.S.), Abbott laboratories (U.S.), AutoGenomics Inc.( U.S.), Celera Group (U.S.), PerkinElmer Inc.( U.S.), Quest Diagnostics Inc.( U.S.), ELITech Group (U.S.), Applied Biosystems Inc.( U.S.), F. Hoffmann-La Roche AG (Switzerland), Transgenomic Inc.( U.S.).

 

Get access to full summary @

https://www.precisionbusinessinsights.com/market-reports/global-genetic-analyzer-market/

 

 

]]>
Global Generic Drugs Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023 Wed, 07 Feb 2018 10:41:02 +0100 http://comunicati.net/comunicati/istituzioni/comuni/emilia_romagna/comune_di_nonantola/468883.html http://comunicati.net/comunicati/istituzioni/comuni/emilia_romagna/comune_di_nonantola/468883.html precision business insights precision business insights

Generic Drugs market: A generic drug is pharmaceutical drug, which is bio equivalent to branded drug. Generic drugs are usually approved after patent expiration of patent drugs.

 Global Market Outline: Generic Drugs Market

 Global generic drugs market is driven by the prevalence of various diseases, need for cost effective drugs for treatment, and government initiatives to increase the use of generic drugs. In addition, favourable regulatory policies, expiry of the branded drugs, and growth in biosimilars segment are expected to boost the generics drugs market. Furthermore, participants in the supply chain such as wholesalers, retailers and pharmacies also benefit from the sale of the generic drugs with high margins compared to branded generics. This emerged as key driver for the growth of global generic drugs market. However, lack of awareness about the availability of generic drugs, competition from branded generics and lack of price control are hampering the generic drugs market.

 

A sample of this report is available upon request @

https://www.precisionbusinessinsights.com/market-reports/global-generic-drugs-market/#ulp-4H8Z4LpNMLEuOnnx 

 

 

Generic Drugs market segmented based on therapeutic area and distribution channel

 

Based on therapeutic area, global generic drugs market is segmented into

·         Cardiovascular

·         CNS

·         Antibiotics

·         Oncology

·         Gastrointestinal

·         Hormones

·         Pain Management

·         Others

 

Based on distribution channel, global generic drugs market is segmented into

·         Hospital Pharmacies

·         Retail Pharmacies

·         Online Pharmacies

·         Others

 

To view TOC of this report is available upon request @

https://www.precisionbusinessinsights.com/market-reports/global-generic-drugs-market/#ulp-c654SbFYO64MsOhu

 

 

Generic drugs market is highly fragmented market, presence of large players and small players. To improve their market position in generic drug market companies are adopting strategies like expanding their market presence through collaboration and entering into new markets. For instance, in January 2017, Medical inhaler company Vectura Group PLC collaborated with Sandoz, a division of Novartis AG, to develop a generic version of an inhaler therapy for asthma and COPD (chronic obstructive pulmonary disease). In January 2016, Momenta collaborated with Mylan Laboratories for the development, manufacture and commercialization of six of its biosimilar candidates, including M834, Orencia (abatacept) a biosimilar candidate. Mergers and acquisitions are key strategies adopted by various market players. For instance, in August 2016, Teva Pharmaceutical Industries Ltd Acquired Allergen’s generic business Actavis Generics to expand their product, R&D portfolio and geographical footprint in generic market.

 

Need more information about this report @

https://www.precisionbusinessinsights.com/market-reports/global-generic-drugs-market/#ulp-14mlyhjMGhVjZqa3

 

 

Geographically generic drugs market segmented into following regions viz. North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. North America generic drugs market is expected to grow at significant rates owing to availability of more number of generics, increase awareness about the generic drugs and favourable regulatory policies and acts such as Affordable Care Act 2010. In Europe region, Belgium and UK expected to grow at notable rates owing to prevalence of chronic diseases, increase in investment on biosimilars, and increase awareness about generic drugs. Asia Pacific Region expected to be fastest growing due to increased government initiatives in usage of generic drugs and increase in awareness about generic drugs. Especially emerging countries like India government initiating different policies and schemes to boost the usage of generic drugs, For instance, Government of India taken an initiative of opening Jan aushadhi stores to make available quality generic medicines at affordable prices to all citizens.

 

Some of the market players in generic drugs market are Mylan N.V. (U.S.), Sun Pharmaceutical Industries Limited (India), Teva Pharmaceutical Industries, Ltd. (Israel), Dr Reddy’s Laboratories (India), Novartis AG (Sandoz International GmbH) (Switzerland), Apotex Holdings Inc. (Canada), Endo International plc (U.S.), Pfizer Inc. (U.S.), Johnson & Johnson Services Inc., (Janssen Pharmaceutica) (U.S.), Lupin Limited (India), Merck & Co, Inc. (U.S.), Mitsubishi Tanabe Pharma (Japan), Momenta Pharmaceuticals (U.S.), Nexus Pharmaceuticals (U.S.), and Novo Nordisk (Denmark) to name a few.

 

Get access to full summary @

https://www.precisionbusinessinsights.com/market-reports/global-generic-drugs-market/

]]>
Crohn’s Disease Treatment Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012 to 2016 and Forecast 2017 to 2023 Tue, 06 Feb 2018 07:02:21 +0100 http://comunicati.net/comunicati/arte/musica/new_age/468695.html http://comunicati.net/comunicati/arte/musica/new_age/468695.html precision business insights precision business insights

Crohn’s disease belongs to a condition called inflammatory bowel disease (IBD) that causes inflammation and damage to the digestive tract. Crohn’s disease usually affects at the end of small intestine and beginning of colon, but inflammation may occur anywhere along the digestive tract. Crohn’s disease may be hereditary or develop due to the malfunctioning of the immune system. Currently there is no cure for crohn’s disease. However, there are many treatments to manage disease symptoms. Inflammation, ulcers, bowel obstruction, malnutrition, colon cancer, and anal fissures are some of the complications associated with the disease. Surgery and drug therapy are some of the treatment options available to treat Crohn’s disease. Some of the anti-inflammatory drugs used to treat crohn’s disease include, corticosteroids and oral 5-aminosalicylates.

 The prime driver for Crohn’s disease treatment market is increase in number of people being infected by the disease. In addition, increase in demand for biologics and high unmet needs within the anti-TNF refractory patient group that presents untapped market opportunities. Strong pipeline and novel mechanisms to treat Crohn’s disease are fuelling the growth of Crohn’s disease treatment market. However, patent expiry of the key drugs and high cost of treatment is expected to hamper the Crohn’s disease treatment market globally. High R&D investment for development of biological drugs and unknown aetiology of the Crohn’s disease further hindering the market growth.

 A sample of this report is available upon request @ 

 

https://www.precisionbusinessinsights.com/market-reports/global-crohns-disease-treatment-market/#ulp-4H8Z4LpNMLEuOnnx

 

Global Crohn’s disease treatment market is segmented based on, drug class and distribution channel

 

 Based on drug class, Crohn’s disease treatment market is segmented into

·         Antibiotics

·         Anti-Diarrheal

·         Immune System Suppressants

·         Analgesics

·         Anti-Inflammatory Drugs

·         Monoclonal Antibodies

 

Based on distribution channel, Crohn’s disease treatment market is segmented into

·         Hospital Pharmacy

·         Retail Pharmacy

·         Others

 

To view TOC of this report is available upon request @

 

https://www.precisionbusinessinsights.com/market-reports/global-crohns-disease-treatment-market/#ulp-c654SbFYO64MsOhu

 

Crohn’s disease treatment market is expected to grow at a significant rate during the forecast period. Growth in biologics development unfolded the opportunities for the new market players as they are most commonly used in Crohn’s disease treatment. Market players are focusing on to develop new products that can treat Crohn’s disease. For instance, mongersen, is investigational therapy for the treatment of crohn’s disease, is being developed by Celgene Corporation in phase 3 clinical trials. Considering the foreseen factors Crohn’s disease treatment market is projected to have a lucrative opportunity for market players.

 

Geographically Crohn’s disease treatment market is divided into five key regions, i.e. North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. North America expected to contribute major share owing to increase in R&D activity and biologics approval to treat autoimmune disease. Furthermore, increase in prevalence and incidence of the Crohn’s disease are expected to drive the growth of the market. According to Crohn’s and Colitis Foundation of America 700,000 have crohn’s diseases in between 1992-2004, and 74% increase in doctor office visits due to crohn’s disease. Asia-Pacific region is expected to create significant growth opportunities for the market players owing to develop infrastructure, R&D activities related to biologics and increase in prevalence of Crohn’s disease in the region. Developing countries such as India and China expected to show the fastest growth owing to increase in R&D investment and healthcare expenditure in these countries

 

Need more information about this report @

 

https://www.precisionbusinessinsights.com/market-reports/global-crohns-disease-treatment-market/#ulp-14mlyhjMGhVjZqa3

 

 

Some of the market players in Crohn’s disease treatment market are Allergan, Inc. (U.S.), AbbVie Inc., (U.S.), Takeda Pharmaceutical Company Limited (Japan), Bayer AG (Switzerland), UCB S.A. (Belgium), Perrigo Company plc (Ireland), Pfizer Inc. (US), Johnson & Johnson Services, Inc. (US), and Ferring B.V. (Switzerland) to name a few

 

Get access to full summary @

https://www.precisionbusinessinsights.com/market-reports/global-crohns-disease-treatment-market/

]]>
Global Cryotherapy Devices Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023 Mon, 05 Feb 2018 14:13:28 +0100 http://comunicati.net/comunicati/arte/spettacoli/468612.html http://comunicati.net/comunicati/arte/spettacoli/468612.html precision business insights precision business insights

Cryotherapy is additionally called as cryosurgery. Cryotherapy is utilization of solidifying specialists, for example, carbon dioxide, fluid nitrogen, freon to stop and regard the injuries, for example, tans (skin), moles and prostate disease. In cryotherapy, a test is embedded into the tissue by the influenced nerve. The temperature of the test abatements to exceptionally cool temperatures and successfully solidifies the nerve. The solidifying inactivates the nerve, subsequently, difficult nerve bothering is soothed. Cryotherapy is a moderately sheltered and successful methods for treating limited nerve disturbance.

 

All inclusive cryotherapy gadgets advertise is mostly determined by developing utilization of cryotherapy in treating different sorts of disease and musculoskeletal conditions, for example, joint pain, rheumatic conditions and fibromyalgia. Likewise, increment in use of cryotherapy gadgets in dermatology for magnificence medications is relied upon to support the cryotherapy gadgets advertise. Moreover, cryotherapy conveys constrained reactions and subsequently encourages quicker recuperation contrasted with customary methods. In any case, some basic symptoms incorporate erythema, torment and hypopigmentation and lower viability of the treatment are the central point anticipated that would prevent the cryotherapy gadgets showcase development.

 

A sample of this report is available upon request @

https://www.precisionbusinessinsights.com/market-reports/global-cryotherapy-devices-market/#ulp-4H8Z4LpNMLEuOnnx 

 

 

Global cryotherapy devices market is segmented based on type of device, application and end-user

 

Based on type of device, cryotherapy devices market is segmented into

·         Cryogun

·         Cryoprobes

·         Gas cylinders

·         Others

 

Based on application, cryotherapy devices market is segmented into

·         Oncology

·         Cardiology

·         Dermatology

·         Pain management

·         Others

 

Based on end-user, cryotherapy devices market is segmented into

·         Hospitals

·         Ambulatory Surgical Centers

·         Others

 

To view TOC of this report is available upon request @

https://www.precisionbusinessinsights.com/market-reports/global-cryotherapy-devices-market/#ulp-c654SbFYO64MsOhu

 

 

Cryotherapy devises market expected to have lucrative growth rate during forecast period owing to increase in demand for treatment options for various types of cancer. As per World Health Organisation (WHO), cancer mortality in the developing countries is expected to reach 6.7 Mn by 2015. Similarly, American Cancer Socity estimates that about 12,280 new invasive cervical cancer will be diagnosed in 2017. This suggests that there is huge demand exists for cancer therapy options across the globe. Market players are focusing on advanced product designing and development to strengthen their product to enhance their sales revenue in cryotherapy devices market. For instance, in October 2015, Galil Medical  launched two cryoablation (killing of cancer cells with extreme cold) products, IcePearl 2.1 CX and IceFORCE 2.1 CX Cryoablation Needles.

 

Need more information about this report @

https://www.precisionbusinessinsights.com/market-reports/global-cryotherapy-devices-market/#ulp-14mlyhjMGhVjZqa3

 

 

Geographically cryotherapy devices market segmented into following regions viz. North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. North America and Europe are expected to show notable growth owing to well-developed healthcare sector with latest technologies. In addition, trained healthcare professionals, and favourable reimbursement policies are also contributing to the growth of cryotherapy devices market in these regions. Asia-Pacific is expected to show fastest growth rate due to untapped opportunities, high patient cognizance of cryosurgery in cancer and skin treatments coupled with the rapidly developing healthcare infrastructure in the emerging Asia-Pacific countries. In addition fewer adverse effects, reduced cost of the procedures, and increase in accessibility of the cryotherapy treatment in Asia-Pacific region is expected to contribute toward the growth of the sector.

 

Some of the players in cryotherapy devices market are Cynosure, Inc.(US), MICHELSON DIAGNOSTIC (UK), Cryonic Medical (France), ZAMAR CARE (Croatia), Zimmer Medizin Systeme GmbH (Germany), MECOTEC GmbH (Germany) and Hakomed Italia (Italy) to name a few.

 

Get access to full summary @

https://www.precisionbusinessinsights.com/market-reports/global-cryotherapy-devices-market/

]]>